Status: Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Participants needed: 74
Trial details
Phase: Phase 2, Phase 3Age: 6-75Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: Jun 10, 2026Locations: 35
Eligibility criteria
Age ≥18 and ≤75 [+4]
Contraindication to leukapheresis [+18]